ePHEDrine Injectable Syringes Recalled Over Sterility Assurance Gaps
Central Admixture Pharmacy Services is recalling 8,942 ePHEDrine syringes nationwide due to lack of validation data for sterilization procedures, creating a potential sterility risk for injectable medications.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This FDA Class II recall lacks reported illnesses or injuries. The hazard—unvalidated sterilization procedures—presents a theoretical risk to product sterility in an injectable medication. Per the severity rubric, risk-of-harm products without reported injury merit a High rating.
Plain-English summary
Central Admixture Pharmacy Services Inc is recalling ePHEDrine in 0.9% sodium chloride injectable syringes (50 mg/5 mL, 10 mg/mL concentration) distributed nationwide. The affected product consists of 8,942 syringes across multiple lot numbers with expiration dates from July 16, 2023 through September 10, 2023.
The recall was initiated because the manufacturer lacks validation data for sanitization cycles used during manufacturing. Without this validation, there is no documented assurance that the sterilization process effectively prevents contamination, creating a potential risk to product sterility.
This is a prescription-only medication distributed nationally. Healthcare facilities, pharmacies, and healthcare providers with this product should discontinue its use and contact the manufacturer or the FDA for guidance on proper handling, quarantine, and return of affected lots.
The recalled product
- Product
- ePHEDrine in 0.9% sodium chloride, 50 mg /5 mL, (10 mg/mL), 5 mL Syringe, Rx only, CAPS Inc., Inc., 7935 Dunbrook Road, Suite C, San Diego, CA 92126, NDC 71286-6004-1
- Manufacturer
- Central Admixture Pharmacy Services Inc
- Category
- Drug — Ephedrine Injectable
- Hazard
- lack-of-sterility
- contamination-risk
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (20)
- Lot: 17-270545
- Exp. 7/16/2023
- 17-270614
- Exp. 7/17/2023
- 17-270885
- 17-270897
- Exp. 7/20/2023
- 17-270980
- 17-270992
- Exp. 7/23/2023
- 17-271268
- Exp. 7/26/2023
- 17-271338
- Exp. 7/27/2023
- 17-271426
- 17-271428
- Exp. 7/30/2023
- 17-271691
- Exp. 8/2/2023
- 17-271843
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27